Notifications
2016_01_28 Data Snapshot
Table 1. Get Full Table
| Barcode | UUID | Date | Type | Category | Notes |
|---|---|---|---|---|---|
| TCGA-18-3406 | 95b83006-02c9-4c4d-bf84-a45115f7d86d | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy L LUSC. No systemic chemotherapy or radiation. |
| TCGA-18-3407 | 4e1ad82e-23c8-44bb-b74e-a3d0b1126b96 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy R tongue treated with radiation. |
| TCGA-18-3407 | 4e1ad82e-23c8-44bb-b74e-a3d0b1126b96 | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy R tongue treated with radiation. |
| TCGA-18-3409 | b09e872a-e837-49ec-8a27-84dcdcabf347 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy basal cell carcinoma of the forehead. No systemic chemotherapy or radiation. Prior malignancy basaloid squamous cell carcinoma of the anal canal treated with chemotherapy and radiation. |
| TCGA-18-3409 | b09e872a-e837-49ec-8a27-84dcdcabf347 | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy basal cell carcinoma of the forehead. No systemic chemotherapy or radiation. Prior malignancy basaloid squamous cell carcinoma of the anal canal treated with chemotherapy and radiation. |
| TCGA-18-3410 | 99599b60-4f5c-456b-8755-371b1aa7074e | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy squamous cell carcinoma of the foot. No systemic chemotherapy or radiation. |
| TCGA-18-3416 | 6eb61cab-8e83-4c18-a59a-ae0985ec9d2e | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy melanoma of the left chest. Prior malignancy melanoma of the arm. Unknown treatment history. |
| TCGA-18-4083 | a33f0741-2161-4818-89f2-ec8ccae57949 | 11/10/2012 | LUSC | Synchronous malignancy | Pt with synchronous malignancy of the larynx. |
| TCGA-18-4721-01A-21-2193-20 | 980eebae-fe8b-4121-8744-92b2448cb72b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-18-5592-01A-21-2194-20 | faeb872c-4711-4218-a772-c660855358f7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-18-5595 | 628b1bc3-825b-4d0e-a4cd-57eeaf98e798 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy cancer of the pharynx treated with cisplatin. |
| TCGA-18-5595 | 628b1bc3-825b-4d0e-a4cd-57eeaf98e798 | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy cancer of the pharynx treated with cisplatin. |
| TCGA-18-5595-01A-21-2194-20 | cf74338e-67f3-4979-a898-8a8c20bc9485 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1070 | 28f899c5-ea17-4df6-83e6-e744e04d0ea1 | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy breast cancer treated with chemo and radiation per path report |
| TCGA-21-1070 | 28f899c5-ea17-4df6-83e6-e744e04d0ea1 | 12/06/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-21-1070-01A-21-2193-20 | c31cbb43-8115-476d-94eb-969f05a749ce | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1071-01A-21-2193-20 | d9fa8294-49b1-4474-bbfb-ffdf6d807382 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1072-01A-21-2193-20 | 7ba5ebaa-df07-4f54-8721-67523cfddc60 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1075-01A-21-2193-20 | 11303d09-57ac-4b08-a3a4-efddc42857a3 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1076-01A-01D | 74916ee7-3546-426a-be7c-5826733a8cbd | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1076-01A-01R | 708fea2e-607d-4221-9525-2828d05365ff | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1076-01A-01T | e9b5e920-a384-4f4d-93f3-c286c40e0e3a | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1076-01A-41-2193-20 | 865ca095-4591-4ca4-8237-a31e6481ccca | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1076-11A-01D | 2d534fea-6b06-4adc-9bc2-100e8c633a91 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1077 | f516991c-5139-4b3e-b605-5a3d90688209 | 06/16/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | unknown treatment history |
| TCGA-21-1077 | f516991c-5139-4b3e-b605-5a3d90688209 | 12/06/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-21-1078 | 0ab8d063-62b4-4d47-82aa-e3351a60029d | 06/16/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | unknown treatment history |
| TCGA-21-1078 | 0ab8d063-62b4-4d47-82aa-e3351a60029d | 12/06/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-21-1078-01A-21-2193-20 | 7c470e40-177f-45c5-96bc-e826294882c5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1079-01A-01D | decf0d88-0cbe-4cca-bda6-e0558dee0e1d | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1079-01A-01R | b11ed052-fc60-4793-b925-829a5b092901 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1079-01A-01T | a4d1337e-54a9-4f41-a3eb-42f9fd9ed07e | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1079-01A-21-2193-20 | 9af4adc0-d07e-4e5d-a656-cfb61bfa2c82 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1079-11A-01D | abf21454-3866-4f6a-a165-f9993004f43d | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-21-1080-01A-21-2193-20 | 19c9ff90-4114-44a5-97be-310997f17334 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1081 | 2afa2fd8-e4d9-4e7b-b387-7e2451764d5d | 09/02/2010 | LUSC | Molecular analysis outside specification | [intgen.org]: Molecular Results off Spec |
| TCGA-21-1081-01A-21-2193-20 | 2d90e6b8-02bf-4665-9803-285243e1ba55 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1082-01A-21-2193-20 | cc44dbbd-5a78-4440-82b5-a2c2d6ef4d7c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-1083 | 0398eae1-7216-4595-80a5-6b117d96e070 | 06/16/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | unknown treatment history |
| TCGA-21-1083 | 0398eae1-7216-4595-80a5-6b117d96e070 | 12/06/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-21-1083-01A-21-2193-20 | 3e8610c1-5e34-4ea1-ad30-37225b06e71a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-5782-01A-21-2194-20 | 5ad0c478-996f-4211-a829-ff7b0fec72d2 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-5784-01A-21-2194-20 | 29d0b45f-ad9b-49a7-af41-979364bc1728 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-5786-01A-21-2194-20 | 98c3c72d-b20b-400d-a53e-8e7d24c3e79a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-5787-01A-21-2194-20 | 37941bbd-aee2-4a9d-891a-a0aa0e8c7714 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-21-A5DI | a7cd7b0f-ab76-4f3f-a2d5-5ec04fe6c4f3 | 06/16/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | unknown treatment history |
| TCGA-22-0940-01A-21-2193-20 | 3d8cb3f0-482e-4acd-bb89-e8530456cd3c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-0944-01A-01D | aba91c63-0dbf-43aa-a165-7edcf8a634b4 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-0944-01A-01R | bfdf791f-80ce-45bb-8731-377c6da15a7e | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-0944-01A-01T | 96553d0a-d94a-46ac-9ae2-3856ec5c56b1 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-0944-11A-01D | 8b1ba57c-fdd5-4f80-b88e-0088145c3227 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1000 | 972476b7-d7f3-4865-b978-0c13f29457cb | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy prostate cancer treated w/ radation |
| TCGA-22-1000 | 972476b7-d7f3-4865-b978-0c13f29457cb | 12/06/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-22-1000-01A-01D | 4f7bc702-52de-40c3-976c-2accc0a879eb | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1000-01A-01R | ac1860cc-17c6-49ac-8b0b-0ac1d0c455e9 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1000-01A-01T | d20150a8-bfb8-49c2-9ca7-4433bfca10a3 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1000-01A-21-2193-20 | 10ac4555-d3e6-4d70-a6ca-2253c0e92de1 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-1000-11A-01D | 70ea4fc2-f84f-43ea-9235-5a0748814cf8 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1002-01A-01D | 28b912af-a630-4219-9aa1-d479508b0cc0 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1002-01A-01R | 4dae830c-a6cc-403b-b259-c9ef7179f7d4 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1002-01A-01T | f2402c60-3d82-4053-a1a3-58a49b4302d1 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1002-11A-01D | bc226b91-5b76-498e-94f1-64619b7e3e2b | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1005-01A-01D | 579db5ec-b747-4435-9534-280e7aeb897a | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1005-01A-01R | 9956ae45-ab62-4658-8df7-2df905a7b11d | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1005-01A-01T | b2dbcf54-2c0f-4f22-98c0-4a490e307033 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1005-11A-01D | 509098f4-d589-4664-a4d8-6f4fbf98ffdf | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1011-01A-01D | 9de5f031-6c27-4048-b49e-591e8ea7e1fa | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1011-01A-01R | 07c9892c-5f7c-412f-9e47-8b47d1db4c2b | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1011-01A-01T | bd049a35-5bf8-463f-9237-b84e45eda038 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1011-01A-31-2193-20 | fcc5d2fc-0775-4e47-9ded-959aba2b92f5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-1011-11A-01D | f17e14d2-ea96-456c-a307-455983c2e162 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1012-01A-01D | 3d3d7a9e-5719-4593-b6e4-e68343b88a3f | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-22-1012-01A-01R | 0b18e84c-4bb6-4d81-99ac-bf43c351fc26 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-22-1012-01A-01T | 7c063a26-71e9-4eea-8867-f1732d922fe6 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-22-1012-11A-01D | 0e36ccf2-8a55-4996-86f3-993ea39c90d7 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 70-80% |
| TCGA-22-1016-01A-01D | e364ac31-ea3c-4f5f-b136-8bf1dcb9e99a | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1016-01A-01R | 6fd3e50d-b815-4e83-a951-6cebec8bbf38 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1016-01A-01T | 87c0463e-91e8-4850-b871-1d063d6ebbb7 | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1016-11A-01D | 0623e8e7-a885-4c79-82f7-385be4d5f7bc | 03/14/2011 | LUSC | Item is noncanonical | Lung Squamous Cell Carcinoma 60-70% |
| TCGA-22-1017 | 25f64b80-0672-4980-9875-956b1699309b | 09/02/2010 | LUSC | Neoadjuvant therapy | [intgen.org]: Subject Positive for Neo-Adjuvant Therapy |
| TCGA-22-1017 | 25f64b80-0672-4980-9875-956b1699309b | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy and neo-adjuvant treatment per enrollment form. |
| TCGA-22-1017 | 25f64b80-0672-4980-9875-956b1699309b | 11/10/2012 | LUSC | Neoadjuvant therapy | Prior malignancy and neo-adjuvant treatment per enrollment form. |
| TCGA-22-4591-01A-21-2193-20 | 5be370a5-e710-4625-8781-43856b8e39af | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-4596-01A-21-2194-20 | 4f5b1160-c56c-4696-90a5-2dffc0569b5f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-4605-01A-11-2193-20 | 5e7c3893-5bf5-4bbb-a98f-ea293538f5ff | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-4607-01A-21-2194-20 | 79c272f1-478c-4a0a-845f-ba113df49b55 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-4609-01A-11-2193-20 | f445dc4e-7f34-47ee-98d7-7f9586084719 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5471 | bece6b8e-5d6c-4dd6-85a3-9b3a9c670aa7 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy melanoma of the neck. No systemic chemotherapy or radiation. |
| TCGA-22-5471-01A-21-2194-20 | 43c5c2ec-d9a9-4fa2-8f12-fa74a31d2e3f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5472 | bd3bf142-7c14-4538-8a76-3c6e140fa01a | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy SCC of the L cheek. No systemic chemotherapy or radiation. |
| TCGA-22-5472-01A-21-2194-20 | 61b44402-a6de-458c-9d45-4b4c258b1590 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5473-01A-21-2194-20 | a79a1a5c-7c23-4c61-9e70-6f1e6c1f5317 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5474-01A-21-2194-20 | 78ec1e12-ed4e-44f3-abb8-aff8b543e2d1 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5477-01A-21-2194-20 | 5162d956-a988-4b03-ae52-d57aa76b1025 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5478-01A-21-2194-20 | 7554f5f0-1c1a-4f71-9d7a-836266435c78 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5479-01A-11-2194-20 | 78c6397c-c479-4743-af4b-61c1bbdc4d3f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5480-01A-21-2194-20 | 52b7abd6-8f9d-4aac-bb99-f0f2c596dac8 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5482-01A-21-2194-20 | 2536d089-b6cf-464e-bd43-9c97b0d8948f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5483-01A-21-2194-20 | 6ff0360e-5a35-4886-8277-c2883374ebb0 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5485-01A-21-2194-20 | 74b2de24-102f-449b-bbf8-ed2e5aaedb63 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5489-01A-21-2194-20 | 04508643-b5be-4165-9d6e-4f3687afdfd7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5491-01A-21-2194-20 | 82d12699-72d1-4283-b45e-35680eb3670b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-22-5492-01A-21-2194-20 | d68eb7ee-e5c5-413b-973b-82cf3ae37d55 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-4532 | 6ee6ca0a-8702-480d-b2d1-9224e7dd9211 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy of the lip and nose. No systemic chemotherapy or radiation. |
| TCGA-33-4532-01A-21-2193-20 | 145f9405-fb5b-432d-8928-063e0d3a7b43 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-4533 | b4ff0f49-b787-48ec-91cc-ee26786ff1bf | 02/26/2015 | LUSC | Case submitted is found to be a recurrence after submission | Other Malignancy form states patient had prior lung squamous malignancy in same lung 9.5 years before TCGA tumor procurement. |
| TCGA-33-4533 | b4ff0f49-b787-48ec-91cc-ee26786ff1bf | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy L LUSC. No systemic chemotherapy or radiation. |
| TCGA-33-4538 | c70a5975-c37b-47cc-9113-427a754807d8 | 11/10/2012 | LUSC | Neoadjuvant therapy | Patient received neo-adjuvant treatment prior to resection of TCGA tumor per enrollment form. |
| TCGA-33-4547-01A-21-2193-20 | 843b8ba9-57ff-4db6-98fb-1c2a508f98b7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-4566-01A-21-2193-20 | 585632a4-48ad-4dda-89f6-c6ad289305f0 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-4579 | 1169b8c3-e5ae-47a8-91db-0ce62a5958e2 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy SCC of the nasal cavity. No systemic chemotherapy or radiation. |
| TCGA-33-4582-01A-21-2193-20 | f6afdaa8-47c3-4483-9a13-62fdc67f4c16 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-4586-01A-21-2193-20 | c153a3c3-eaff-4a5b-b4fd-dc4d467669e7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-4589 | 49f975ea-a1cf-4a9b-bf13-030c68cc99e4 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy SCC of the tongue treated with locoregional radiation. |
| TCGA-33-4589 | 49f975ea-a1cf-4a9b-bf13-030c68cc99e4 | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy SCC of the tongue treated with locoregional radiation. |
| TCGA-33-4589-01A-21-2193-20 | 78114d62-a9cb-4bfa-8c47-a84e9c53802f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-6737 | afedf3fb-fc77-45a7-bdcd-2c78706a0f8a | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy Hairy Cell Leukemia treated with 2-CdA and Pentostatin. |
| TCGA-33-6737 | afedf3fb-fc77-45a7-bdcd-2c78706a0f8a | 11/18/2011 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-33-6737-01A-13-2194-20 | f15f6e1d-a3f0-4de4-9060-833a3989022f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-33-6738-01A-13-2194-20 | 5dcec6e8-27e0-4674-b842-8f2d2542d907 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-2596-01A-21-2193-20 | 9d1b859e-95d7-43d1-b71a-c0a0c240ccda | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-2604 | cee6e9f6-6d7e-4096-a9bc-2cce004fb218 | 09/02/2010 | LUSC | Prior malignancy | [intgen.org]: Prior Malignancy |
| TCGA-34-2604 | cee6e9f6-6d7e-4096-a9bc-2cce004fb218 | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy bladder cancer treated w/ locoregional radiation. |
| TCGA-34-2604-01A-21-2193-20 | cf27663d-6ff3-4102-948c-c0c712af54d0 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-2605 | 9335e4df-9974-47ec-84c4-256cd33522f2 | 09/02/2010 | LUSC | Prior malignancy | [intgen.org]: Prior Malignancy |
| TCGA-34-2605-01A-21-2193-20 | 79a77711-5efb-4811-9e36-c6823526a48a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-2608-01A-11-2193-20 | f3b4f474-f6b9-47aa-bcf8-a06304109a51 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-2609 | 257650bd-2e2b-4680-b77b-f9268b3af4ee | 09/02/2010 | LUSC | Prior malignancy | [intgen.org]: Prior Malignancy |
| TCGA-34-2609-01A-21-2193-20 | ce27724e-e32d-4576-a458-17ee97966504 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5231-01A-22-2194-20 | 70790e8d-ce93-491e-8b1f-f3a5b60871b5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5232-01A-22-2194-20 | df107ef1-536f-4ba9-aed3-7bed52caa45c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5234-01A-21-2194-20 | a26c5140-ea1f-4fc1-adbb-a3c8203bd19c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5236-01A-22-2194-20 | 428e8766-529c-4372-8ea0-908252cd825c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5239-01A-22-2194-20 | fc556f8e-523f-4dc1-926c-bdc0eb9debb9 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5241-01A-21-2194-20 | 0140324e-7bca-4fbb-b771-73ccd1a4c15a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5927-01A-13-2194-20 | 285a2366-5d39-41d4-ba6a-36515454fcb6 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5928-01A-13-2194-20 | 98d56989-dbfb-4d7a-91f5-13f9163bab5f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-5929-01A-13-2194-20 | b2b7dd0b-8713-45ee-9dfe-351b895c2046 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-34-7107-01A-13-2194-20 | b00c4a7d-5025-40e5-be42-dac01b3de7fe | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-3789-01A-21-2193-20 | 25a5c25c-2520-4a48-8f96-4b1798af4de6 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-3792-01A-21-2193-20 | f7e9d4d4-3b43-4f96-aaaf-75dbc77f68d4 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-3915-10A-01D-1086-04 | 677f21bb-6528-4f5a-8914-b5a6255ae6ed | 07/02/2013 | LUSC | Barcode incorrect | Incorrect barcode and UUID (TCGA-37-3915-10A-01D-1086-04:677f21bb-6528-4f5a-8914-b5a6255ae6ed) replaced by correct barcode and uuid TCGA-18-4083-11A-01D-1086-04:1ee0824c-09b3-47ce-897d-627b97966809 |
| TCGA-37-4129-01A-21-2193-20 | 8db5bd89-429b-4872-9ca0-fb72e95cf504 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-4133-01A-21-2193-20 | 759891ff-ab70-4687-bd59-b6df4d18f93f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-4135-01A-21-2193-20 | 7cdeb372-38d2-46a5-a868-cac875e0c524 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-4141-01A-11-2193-20 | b464e455-cab7-456b-89dc-ca193fd7a25f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-37-5819-01A-21-2194-20 | 9218f291-efd3-41a3-a784-7934ea10fe03 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5011-01A-21-2194-20 | 543782e2-71d3-4cc2-80e4-11b9a0eb15ce | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5016-01A-21-2194-20 | 9d441074-5562-43c7-8158-903e11fb1eaa | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5019-01A-21-2194-20 | a928f1c8-ed6b-4908-8174-03bf26fd1fa4 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5021-01A-21-2194-20 | 34e208a6-3752-47a1-87f3-ae1c02612d17 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5022-01A-22-2194-20 | 441d3e63-041c-48f0-bc13-9febd802aab8 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5024-01A-22-2194-20 | 82c886e2-5803-46e5-9553-949321c21d34 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5027-01A-22-2194-20 | 65da1c24-f058-4754-80b1-bb45247f835b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5028-01A-21-2194-20 | 424c5902-5b4c-4576-a19b-f3e7aab0ff1d | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5029-01A-21-2194-20 | bcb62b1f-2852-4823-8028-9845e480e34f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5030-01A-21-2194-20 | 6bf62267-1f99-4080-ad9d-caf0f7b60b68 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5031-01A-21-2194-20 | 02171381-ad60-4e7b-a56d-c0a3f129dcaa | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5034-01A-21-2194-20 | 9088cd2b-f01a-4e61-949b-026e4be3479a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5035-01A-21-2194-20 | 3c25960c-f4f3-493f-8cff-b039e73b921e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5037-01A-21-2194-20 | 9864ab85-daea-4018-b513-0f577c9391f4 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-39-5039 | ffb83f21-06d9-4e52-a2d0-e85c13f4037f | 01/09/2011 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-39-5039 | ffb83f21-06d9-4e52-a2d0-e85c13f4037f | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy prostate cancer, treated with hormone therapy and locoregional radiation. |
| TCGA-39-5040-01A-11-2194-20 | d5a08f32-ad9a-45d2-8f8b-66283eafad42 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-2578 | 37f5457e-21d9-4b79-95d5-ded6f2e43087 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy R LUAD. No systemic chemotherapy or radiaiton. |
| TCGA-43-2578-01A-21-2193-20 | 8533dc60-fcd4-4b70-af5d-624df2d66eb2 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-2581-01A-21-2193-20 | 25c27349-3d97-4602-aa07-8187a7c97788 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-3394-01A-21-2193-20 | 16838c14-8069-48d4-b57a-f06db613503b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-5668 | f5ad138c-1714-41e9-9c2d-c88050bec407 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy basal cell carcinoma of the skin. No systemic chemotherapy or radiation. |
| TCGA-43-5668-01A-21-2194-20 | e34afcb4-f3ec-4f28-b419-cf55da46f62e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-5670-01A-11-2194-20 | 75fb3562-d7fc-459c-acc9-5b66d16eb7fa | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-6143-01A-13-2194-20 | 01f9ec9b-2018-4773-aac3-afc9218f8057 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-6770-01A-13-2195-20 | ebc6f011-b3ec-4c3a-b834-042da6b23280 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-6771-01A-13-2195-20 | 6d6d5925-f180-4866-bcb1-f954a2da17f7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-7656-01A-13-2195-20 | 8f489848-549d-41e4-9a75-db8aea47589f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-7657 | dbece124-c042-4adc-8136-90e7940ee6ad | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy uterine cancer. No systemic chemotherapy or radiation. |
| TCGA-43-7658 | a6ec75d4-1c90-4527-bfae-aa91d2dae082 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy basal cell carcinoma of the nose. No systemic chemotherapy or radiation. |
| TCGA-43-7658-01A-13-2195-20 | 68a07bc1-8c04-4887-a120-c3efa5e439d2 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-43-A474 | ae2c650c-600b-4c58-893b-7fd73d44af47 | 07/16/2013 | LUSC | Prior malignancy | Patient had a prior skin malignancy. No systemic radiation or chemotherapy. |
| TCGA-46-6025-01A-13-2194-20 | 55f36d96-6b14-4aee-97fe-a846962e8512 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-46-6026-01A-13-2194-20 | 1f974ba9-6993-4575-8372-32673ea3fdd9 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-51-6867 | 3b195845-0050-49cb-b639-1fe85a131ebe | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy cancer of the larynx treated with locoregional radiation. |
| TCGA-51-6867 | 3b195845-0050-49cb-b639-1fe85a131ebe | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy cancer of the larynx treated with locoregional radiation. |
| TCGA-51-6867-01A-13-2194-20 | df2fd16f-c857-4ec5-8ed8-07db1d345f50 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-52-7810-01A-13-2195-20 | 6e66e4f7-d938-4cf6-85e3-ea40f8838b95 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-52-7811-01A-13-2195-20 | feb2a011-9826-4922-8fdb-e702a929a793 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-52-7812-01A-13-2195-20 | e78b8041-fe48-46e1-b651-a19c69be92e6 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-5897-01A-12-2194-20 | 59c57cc0-8672-4e6d-8248-65c676f2db8b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-5898-01A-12-2194-20 | f1648030-8469-478a-99e6-13ec906dca7e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-6545-01A-13-2194-20 | acdc06c7-b306-4fc8-9a28-68b2a9a78d4c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-6546-01A-13-2194-20 | d3df09a4-a843-49d4-84b3-e7822b797bdc | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-7221 | 1dba835e-cbe9-41e0-883d-50bf86bc7821 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy basal cell carcinoma of the skin. No systemic chemotherapy or radiation. |
| TCGA-56-7221-01A-13-2195-20 | ce08b9c6-00c0-45d0-b84d-f0bce0fdc469 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-7222-01A-13-2195-20 | 727b199a-6c1b-4d39-9e96-e983ca7ba1c9 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-7730-01A-13-2195-20 | 4b68ddb5-5d40-4009-8269-2262e4b2a97a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-56-8305 | d5e94dcf-994f-48a0-b491-bbbf1c2a6783 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy B-cell chronic lymphocytic leukemia. No systemic chemotherapy or radiation. |
| TCGA-56-8308 | 399c936e-ba68-4040-98d4-917a87dad603 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy melanoma of the R eye. No systemic chemotherapy or radiation. |
| TCGA-56-8504 | 9ee64a87-7224-461c-94da-29710d73164f | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy skin cancer. No systemic chemotherapy or radiation. |
| TCGA-56-8623 | 513c5f34-dc6e-4caa-81cc-907fd6a825b1 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A | a5370483-6bdd-4e2a-9b4b-ec1eb381052b | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11D | 2327bab1-e352-4c43-ab40-6162e8632c26 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11D-2386-00 | (none) | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11D-2391-01 | 2aa6f51a-e0fa-4bdb-830c-80b79c59cfc9 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11D-2395-08 | e2bca154-9ff3-42a6-a5bc-0daa14080c92 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11D-2398-05 | dd64f5ba-b9b8-4e7b-81eb-fa9318febede | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11H | 5a676d7d-0b8d-48fb-b898-0eb023a871e1 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11H-2402-13 | 6f688bcb-0534-4a50-a39d-a3a149165694 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11R | 51ded92f-852f-4445-96b2-dd9db1544a9d | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11R-2403-07 | 00d6443c-c6a8-427c-8137-55df848ff2b1 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11R-A28V-07 | 265c0257-54b6-4b79-8c9a-d56ca8bbdb48 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11W | 1577d666-1852-49cf-a101-076d851b8ce4 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-01A-11W-A29C-08 | 7d5ca750-1b71-4887-b4a1-865ecf47566c | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A | 39c2e6c5-379e-4ffa-b02c-e1db298b34f7 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A-01D | a4d9f761-ece9-4a6b-8818-ecf4a8f7d380 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A-01D-2386-00 | (none) | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A-01D-2391-01 | a3219216-997d-44a5-be11-0672c8b3ed04 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A-01D-2395-08 | d9fffb10-ae12-43ad-983b-1e2336f915a3 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A-01W | 84099332-37fa-4bd3-8ab4-77ae7e065a3e | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-10A-01W-A29C-08 | a1b2b194-842c-438e-b81b-069963ef2b96 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A | 26368154-1ed7-4471-87b9-d50d5fe8046b | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01D | f1090757-a85d-4702-a16f-0ee35284c45d | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01D-2386-00 | (none) | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01D-2391-01 | 7c9e5386-1540-40f2-96ed-c06d752598df | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01D-2395-08 | 3cffe6b0-3aef-413a-a9a9-4a2fcefff6ad | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01H | 258a054e-b0ec-4215-81c9-8e1c715abc9b | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01H-2402-13 | 77eccef5-254d-4ddc-a70f-576436278e0a | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01R | 7402c87f-c9b7-451f-9b8d-a8979bf0d98b | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01R-A28V-07 | 9fe04d07-57ba-434f-8254-184fe00ab23e | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01W | c2fc5209-3582-42d3-a8cc-c583d52b4d62 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-56-8623-11A-01W-A29C-08 | 9ab7e83a-6ff4-4343-9478-4f82cdc34809 | 09/05/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signature of the tumor DNA and RNA cluster with the normal controls. Their analysis suggests that the purity of the tumor is very low. Therefore, the data from this patient should be used with caution. |
| TCGA-60-2695 | acae4e48-57de-40c5-9ae5-4386144ebaea | 10/11/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-60-2695-01A-21-2193-20 | ec5712a3-b8ad-4fad-a544-e815bffacece | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2696 | bff77f70-973a-4b49-8fd9-4a767f5df2c0 | 10/11/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-60-2696 | bff77f70-973a-4b49-8fd9-4a767f5df2c0 | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy breast cancer treated w/ tamoxifen and radiation and tymus cancer treated w/ cancerrboplatin and Paclitaxel |
| TCGA-60-2696-01A-21-2193-20 | 3a198ed8-723a-4655-8fb2-74e042bea193 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2697 | 3c112114-6a8b-4aea-9349-6dffbaad078d | 11/10/2012 | LUSC | Neoadjuvant therapy | Patient received neo-adjuvant vincristine, CCNU, cytoxan, doxirubicin, and cisplatinum prior to resection of TCGA tumor |
| TCGA-60-2697-01A-21-2193-20 | 7125f62c-3ad3-45a5-aa83-a9052c5669ed | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2698 | fd9ee494-65fe-4de4-adff-7952a059b17f | 10/11/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-60-2698-01A-21-2193-20 | f57a7f9b-23c2-4a93-9322-9df5bc51eb99 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2703-01A-21-2193-20 | 68eb1b05-eb54-4b64-a7e5-6e76e09e6b11 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2704-01A-21-2193-20 | ffb8aceb-b5f5-4722-8051-74a36e32cfe3 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2706-01A-21-2193-20 | ef42af10-10c8-4c5f-92f7-aa8fec60634a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2708-01A-21-2193-20 | 64455e1c-360e-4627-8c8a-55c27c7705c3 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2709-01A-22-2193-20 | 6542146d-b4b9-4ed7-9fcf-b511ad1c43d7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2710 | b28e3be1-9843-4204-b999-b3e2a909c7bd | 11/18/2011 | LUSC | Neoadjuvant therapy | [intgen.org]: Subject Positive for Neo-Adjuvant Therapy |
| TCGA-60-2710-01A-21-2193-20 | fe48e710-052c-48da-a9ba-7705e7451700 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2711 | 1f11de87-a5fe-49fd-80c1-e279b2bc69de | 10/11/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-60-2711-01A-21-2193-20 | 00a75e05-8928-432f-ae8f-3acbb88a182b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2712 | f355cd59-eaa9-46c7-ab07-b90a7afc875c | 10/11/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-60-2712 | f355cd59-eaa9-46c7-ab07-b90a7afc875c | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy L breast cancer treated w/ locoregional radiation (TCGA tumor is in L upper lobe of lung) |
| TCGA-60-2712-01A-21-2193-20 | 048d4992-bd37-46bb-97c0-7cfaf69cc61d | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2713-01A-21-2193-20 | aef657e5-4555-4842-946a-7883c8f8b362 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2714 | 705a4688-f10f-4e6a-aed9-6efc3b3b9989 | 11/10/2012 | LUSC | Neoadjuvant therapy | Patient received neo-adjuvant carboplatin, taxol, and cisplatin prior to resection of TCGA tumor |
| TCGA-60-2714-01A-21-2193-20 | 089deb86-da03-40f6-83c0-c6cc33a47ab3 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2715 | f3e67161-1532-4b50-a9b5-0da80410c4d7 | 09/02/2010 | LUSC | Prior malignancy | [intgen.org]: Prior Malignancy |
| TCGA-60-2715 | f3e67161-1532-4b50-a9b5-0da80410c4d7 | 11/10/2012 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Prior malignancy of the larynx treated w/ chemotherapy and radiation. |
| TCGA-60-2716-01A-21-2193-20 | b1371353-26af-4c41-b52e-dc7a0848ec98 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2719-01A-21-2193-20 | 7d294b6d-9ac2-4e67-a2e0-5a7530db840c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2720-01A-21-2193-20 | 2c8e7971-12b3-4301-856d-38e55ed745d5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2721 | bcd78677-98d5-4403-8313-e1fbd76e8ef7 | 10/11/2010 | LUSC | Prior malignancy | [intgen.org]: Subject has Hx of prior malignancy |
| TCGA-60-2721-01A-21-2193-20 | d292d1eb-ee65-4573-8662-faedf11fa9ad | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2724-01A-21-2193-20 | ec285ff7-4d23-4739-9946-065f534d6fe8 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2725-01A-21-2193-20 | dc18de9c-9edf-48c8-9a00-3598aad84aa5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-60-2726-01A-21-2193-20 | 49bf0bf2-031f-4d67-83a4-abc14322c298 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-5128-01A-21-2194-20 | c514a02d-1b88-48ad-8d47-e225eda23780 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-5131-01A-21-2194-20 | 494e308b-4cd4-44ac-b556-9ea1a95be212 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-6202-01A-13-2194-20 | 52080758-70e0-4463-8ef4-ebb8ba5e19d2 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-7020-01A-13-2194-20 | ff0190fb-eb34-4331-9068-2c02bf067253 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-7021-01A-13-2194-20 | 81db3e1a-0540-49d0-a6fa-c2561c14fe7c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-7022-01A-13-2194-20 | 51130a95-5996-4288-ab16-504f6d8b8314 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-63-7023-01A-13-2194-20 | ab830587-6698-4cd1-9690-d620819ef10f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2727-01A-21-2193-20 | d494adb7-9e76-4717-b142-47521c544e9a | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2737-01A-41-2193-20 | 46aec886-20f0-47f3-ba36-3ba0b036f764 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2758-01A-11-2193-20 | 4dda1522-0094-4b54-b413-ad6d92df3ad9 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2766-01A-21-2193-20 | ba82b423-e845-4d6f-b8bf-aa44344e0e2e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2767-01A-21-2193-20 | 2046ba58-db49-44ba-b6ae-fb9eee38a211 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2768-01A-21-2193-20 | 28068872-a9b1-4e43-b5a4-92d1cdd03408 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2769-01A-11-2193-20 | 5de8582a-34f9-4ea2-943d-bf46f07c06e0 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2770-01A-21-2193-20 | e858ee92-0438-48e9-a70d-80ef2c0ad539 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2773-01A-21-2193-20 | 1d33bdef-845d-4bf8-bc13-72113614a4c8 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2777-01A-21-2193-20 | 129560c0-36c3-4f01-98ed-606e583390d4 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2778-01A-11-2193-20 | f5dca0d5-550d-4107-b6ad-9d347a39afa5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2781-01A-21-2193-20 | b307a0f2-a455-4b20-b866-8da02f3d8fd4 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2782-01A-21-2193-20 | 6cafe140-32f0-40b7-8d8b-60e7c76e4c0c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2783-01A-21-2193-20 | 74291822-bcab-4871-ad7c-cf2023ec7c2f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2785-01A-21-2193-20 | a8bd2e87-dee1-4801-8742-25eacf7d7484 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2788-01A-21-2193-20 | c1620625-664d-4fec-9ddc-ace245378ca7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2790-01A-21-2193-20 | 03a83493-5aa7-4c60-9fb0-9d4112d0fec2 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2791-01A-21-2193-20 | cd4f93c9-f2fe-4271-ab18-78e528cfb9ad | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2794-01A-21-2193-20 | ab258a4f-7597-4592-81c1-9f8aa1b7bf0c | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2795-01A-11-2193-20 | e145986b-e6d4-4e31-bf1e-b242af22f436 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-66-2800-01A-21-2193-20 | 46d73760-a073-4776-a709-4c8a47d0d076 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-68-7756-01A-13-2195-20 | ed06c7b1-cc32-46c2-810c-310112f4c7a8 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-68-8250 | 7b982d5e-3a7d-40ac-bd25-6044c62879b6 | 11/10/2012 | LUSC | Synchronous malignancy | Pt with synchronous R LUAD, mixed subtype and L LUSC. |
| TCGA-70-6722-01A-13-2194-20 | 7f55ab0d-c1e6-40bb-822c-a2a007f6f2aa | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-70-6723-01A-13-2194-20 | c11267c5-85c9-41fc-9d22-9531b264afa3 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-6842-01A-13-2194-20 | 0b3eb76b-445c-4a34-9e9c-d626c5a79b80 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-6843-01A-13-2194-20 | ad48f945-91c3-4ef1-8ecd-4dfbb5449718 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-6844-01A-13-2194-20 | 7490a6fd-28ce-444d-800c-5d8da101263e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-6845-01A-13-2194-20 | 53a0c948-51c5-45f0-ae9e-a27679f2849f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7139-01A-13-2195-20 | 170fc88b-90da-456b-b2d2-b8675c357b8e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7140 | 107f6b9a-2883-4499-a40a-ec25bc834a06 | 01/24/2012 | LUSC | Prior malignancy | [intgen.org]: Patient had prior malignancy of basal cell carcinoma; treated surgically only. |
| TCGA-77-7141-01A-13-2195-20 | 0f4cb2ec-80f5-4ecf-b1fe-87862265e560 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7142-01A-13-2195-20 | f8ffcd7b-8e62-42ab-a042-d9b8e2eb028e | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7335-01A-13-2195-20 | cbbac7ba-2c9e-48da-a60b-d48636e498d9 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7337-01A-23-2195-20 | 52200f31-4605-44ce-838c-91729bfe62fb | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7338-01A-13-2195-20 | 79c97d84-243a-4530-b77f-9f1228a2217f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7463-01A-13-2195-20 | a0e4c36a-85d9-44d7-9423-307a37ab300b | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-7465-01A-13-2195-20 | 9cbef841-960d-477c-8e8c-96a3c7353478 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-77-8138 | 283af87a-f962-47ab-8a7b-4fcd7e45cdf6 | 10/31/2012 | LUSC | Item does not meet study protocol | Subjects history of prior malignancies is unknown, which does not meet study protocol criteria. |
| TCGA-77-A5GA | ce137f49-d12b-4112-825a-e673545f54e5 | 06/16/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | unknown treatment history |
| TCGA-79-5596-01A-11-2194-20 | 7ffba9b0-d42d-4078-b1a5-f83bcb3c39e1 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-6175-01A-13-2194-20 | 1251f240-d00c-412d-bd87-07cffed92f72 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-6560-01A-13-2194-20 | e70edfac-57af-42e6-a823-2b20b8e9e203 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-6561-01A-13-2194-20 | 9a0f38cb-9131-4cb6-8874-853dd8c89a48 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-6798-01A-13-2194-20 | 8e798033-e911-4140-9060-f2bdcfddb539 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7696-01A-13-2195-20 | f20b163a-ad2d-46b0-869e-f6a742d4b8ac | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7697-01A-13-2195-20 | 2be75562-f756-4876-a44a-9c363f34530f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7698-01A-13-2195-20 | 4906559e-b052-4afa-863c-afa098b38d54 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7699-01A-13-2195-20 | 097a545f-3da7-43fa-a441-f6417346ecb5 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7710-01A-13-2195-20 | d8a44db0-50c4-4f6e-bae7-6d42afa90554 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7843-01A-13-2195-20 | 777f34fc-0425-4901-a25e-8f841fa64f26 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7844-01A-13-2195-20 | 8e02f3ec-c4a3-447b-b2f3-c215bd907ac7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-85-7950-01A-13-2195-20 | a454299d-b074-4dd9-adf3-3e48f4473543 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-90-6837 | 0e515ab8-99f9-43d9-a621-8fe9ede828ec | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A | 0120344d-7346-409f-8518-ef7b13f867ff | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11D | a97debd8-fbee-453f-bc69-b7fb6a82fd52 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11D-1941-02 | 3f2c122a-ec03-4102-9372-e1fc10f24519 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11D-1943-01 | 2d975715-bd19-40d7-922f-7baff9b42323 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11D-1945-08 | 60311583-a64f-4fea-b6d0-a4a50bbacd6e | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11D-1947-05 | 14ed8af0-3c28-45f9-8ffb-9852e9669804 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11H | 07263f7e-70c6-4770-a205-189e3da0db3e | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11H-1948-13 | ba280f24-7829-4ecd-b255-b93547a1ac46 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11R | 922955d3-59ab-48c8-82f7-eb0f293fae2b | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11R-1949-07 | 91c5d28b-85af-49ff-8307-140707d13d0e | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11W | 9372df66-a11d-4130-bbe4-bb974223a809 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-11W-1984-08 | b9625f6e-27d3-4aca-8d50-cdad8985cd90 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-01A-13-2194-20 | 56eec851-cabd-46ab-af62-812dae018005 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-90-6837-01A-13-2194-20 | 56eec851-cabd-46ab-af62-812dae018005 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A | b471831a-eda9-425a-a3f2-55d62f599945 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A-01D | 3ba890ac-e77f-43cb-9c61-261ffcf691f0 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A-01D-1941-02 | 9f9ddc96-b741-4d1f-bb16-0a43fc2a8df2 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A-01D-1943-01 | 870232a0-e907-4e5d-abba-15c9259190d9 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A-01D-1945-08 | 987044e8-c464-4ee7-a350-3ebf4e72897e | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A-01W | cabaeadf-9733-4d74-bd3d-bf540aea0bfb | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-10A-01W-1985-08 | 34162874-b7d5-40a0-806f-82dbe1b0ef0c | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A | 0945bee5-8d09-44a3-ac01-8e8064d2b094 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01D | 2c2113a0-3bf1-4a6b-9fac-2641a517899d | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01D-1941-02 | bc9488ee-8a3a-4a38-ad1b-8ec2d31c8f4a | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01D-1943-01 | adb5f857-94a2-4a35-af55-2c2d6417e064 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01D-1945-08 | 96151621-a6b3-4fdc-921d-1260680db414 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01D-1947-05 | e690f806-b34b-4910-aff2-770d6a61a4cf | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01H | 8fe774b6-8e06-4a0e-80f0-df65f843e0e2 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01H-2124-13 | 4997473b-8e48-4b0f-9927-6f84163c13b0 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01R | 300448ff-df63-4b80-9a14-42a3189efac2 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01R-1949-07 | 6178dbb9-01d2-4ba3-8315-f2add186879a | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01W | ca07d453-5c6c-4504-acd9-bd84fad62168 | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-6837-11A-01W-1984-08 | bebbd78d-7473-43d1-af19-f540c919a12f | 09/04/2014 | LUSC | BCR Notification | Possible tumor/normal sample swap, cross-contamination, and/or sample purity issues. The sequencing and characterization centers have reported that molecular signatures from the DNA and RNA from the tumor and normal tissue, as well as DNA from the blood derived normal, do not cluster with the expected sample types. This suggests the tumor and normal samples may not be labeled correctly; all genotyping results confirm that all samples are from the same patient. Data from this patient should be used with caution. |
| TCGA-90-7766 | 3fdf941e-40ec-43b6-b6e3-31a0861bd5b8 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy of a gynecological cancer. No systemic chemotherapy or radiation. |
| TCGA-90-7766-01A-23-2195-20 | dd8497bc-44e4-4128-80b0-64b3ca838c64 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-90-7767-01A-13-2195-20 | 4a4135f8-825b-457a-a65c-edf07e0215cb | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-90-7769-01A-13-2195-20 | 71d2cccb-ba7a-47f2-96d0-11b7b3f0c20f | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-90-7964 | 6e6b8596-76aa-49f5-a997-46ebc0e43934 | 11/10/2012 | LUSC | Synchronous malignancy | Pt with synchronous R LUAD. |
| TCGA-92-7340-01A-23-2195-20 | bbdcf945-baf7-42ed-ab05-6f2dcb81c323 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-94-7033 | 3351b902-9b7e-4b90-bf6b-bcf74be00bc1 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy bladder cancer treated with locoregional intravesical therapy |
| TCGA-94-7033 | 3351b902-9b7e-4b90-bf6b-bcf74be00bc1 | 11/10/2012 | LUSC | History of acceptable prior treatment related to a prior/other malignancy | Prior malignancy bladder cancer treated with locoregional intravesical therapy |
| TCGA-94-7033-01A-13-2194-20 | 95f1fbdc-e59b-4825-b63e-c71b23b2f6e9 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-94-7557 | ea741488-5475-4a3d-b9fe-81722f129974 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy prostate cancer. No systemic chemotherapy or radiation. Patient with synchronous LUAD, mixed subtype. |
| TCGA-94-7557 | ea741488-5475-4a3d-b9fe-81722f129974 | 11/10/2012 | LUSC | Synchronous malignancy | Prior malignancy prostate cancer. No systemic chemotherapy or radiation. Patient with synchronous LUAD, mixed subtype. |
| TCGA-94-7557-01A-13-2195-20 | b55c5cd9-2ac9-4b08-bebd-acd943bf9521 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-94-7943 | aecf85cc-058c-46f3-9cdc-3573ac3b8438 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy lung cancer. No systemic chemotherapy or radiation. |
| TCGA-94-7943-01A-13-2195-20 | 78584fca-e293-47bf-b2a0-bcaa476544a7 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-96-7544-01A-13-2195-20 | f2806a36-bdd6-48dc-9c91-c5eddff6a4ec | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-96-7545 | 4ca13c92-84b4-4edf-842a-b20b7e713415 | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy bilateral LUAD. Prior malignancy R LUAD. No systemic chemotherapy or radiation. |
| TCGA-96-A4JK | 613adbb3-c2d1-4992-9953-c4fadd249001 | 08/14/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | Patient was given BCG for the prior bladder cancer, which was not approved by the lung group as an acceptable prior treatment. (per Kristen Leraas/BCR TCGA-2222) |
| TCGA-98-7454-01A-13-2195-20 | fed5fc80-909c-45a8-a5d1-06c865837c32 | 03/12/2012 | LUSC | Item is noncanonical | LUSC Proteomics MDA |
| TCGA-98-8020 | ffb53b81-c1ed-473c-bdcd-b325b02e22ae | 10/31/2012 | LUSC | Prior malignancy | Prior malignancy bladder cancer. No systemic chemotherapy or radiation. |
| TCGA-J1-A4AH | 99daa971-31d0-4c37-9c12-b0dc42ddd19b | 07/16/2013 | LUSC | Synchronous malignancy | Patient was diagnosed with a thymoma at same time as this lung mallignancy. |
| TCGA-NK-A5D1 | 80aa8e99-41d5-422f-a1bb-69599aa8236f | 06/16/2014 | LUSC | History of unacceptable prior treatment related to a prior/other malignancy | systemic treatment given to the prior/other malignancy |